5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates

The Medical sector’s Q4 2025 reporting cycle is ramping up with overall fourth-quarter earnings expected to fall 2.4% while sales are projected to rise 8.7% year-over-year; among the 11.7% of companies that had reported by Jan. 28 (26% of sector market cap), earnings fell 15.5% and revenues rose 10.3%, and 42.9% beat both EPS and revenue. Bellwether J&J already beat estimates, Roche was pressured by adverse FX, and Sanofi delivered mixed results; Zacks highlights five beat candidates with current Zacks ranks and Earnings ESPs — Zoetis (Q4 est. EPS $1.40, rev $2.37B; ESP +0.84%, report Feb. 12), Pacira (EPS $0.85, rev $196.99M; ESP +7.38%), Apellis (loss $0.41, rev $194.37M; ESP +4.52%), Acadia (EPS $0.12, rev $292.64M; ESP +14.92%), and Denali (loss $0.75, rev $18.47M; ESP +6.11%) — with Denali also awaiting an FDA decision on tividenofusp alfa on Apr. 5, 2026.

Analysis

Market structure: Short-term winners are mid‑cap specialty names with positive Earnings ESP (ZTS, PCRX, ACAD, APLS) and Denali (if collaboration revenue holds), while large pharmas with FX exposure (e.g., SNY, Roche peers) see reported sales compression of ~3–7% if USD trends persist. Animal‑health (Zoetis) and procedure/pain-management products (Pacira, Iovera, Zilretta) show higher pricing power and resilient demand — expect 5–15% revenue outperformance vs cyclical pharma in the next 4 quarters. Cross‑asset: material beats will compress equity CDS and credit spreads for small biotech issuers (tighten 20–50 bps), knock options IV down 15–30% post‑print, and limit FX volatility benefits if the USD re‑strengthens.

Risk assessment: Key tail risks include an FDA negative on Denali’s tividenofusp (Apr 5, 2026) causing >30% downside, a safety headline for Librela/Solensia trimming ZTS growth by 5–10% next quarter, or a rapid USD rebound shaving sector sales 2–5% QoQ. Immediate (days): earnings beats can move names 5–20% intraday; short term (weeks): guidance revisions drive re‑rating; long term (quarters/years): continued secular growth in companion animal and rare‑disease drugs supports multiples if commercial execution holds. Hidden dependencies: milestone/collab revenue recognition (Denali), Medicare/pricing policy shifts, and inventory swings at hospital/clinic customers.

Trade implications: Favor asymmetric, size‑controlled longs into names with high EPS ESP but hedge IV risk — e.g., ZTS and PCRX sized 1–3% each; use call spreads to cap premium. For Denali, use calendar or vertical call spreads ahead of Apr 5 to buy convexity (target 1% exposure, max loss pre‑defined). Implement pair trade: long ACAD (1.5%) vs short SNY (1.5%) to capture product momentum vs FX headwind. After earnings, harvest gains within 2–6 weeks; if guidance disappoints, cut at 8–12% loss.

Contrarian angles: Market may underprice Denali’s platform optionality beyond tividenofusp — a clean FDA action could re‑rate organizers by 30–50% into 2026; conversely, FX concerns may be overplayed for firms with hedging programs (look for explicit hedge ratios in filings). Historical parallel: animal‑health outperformance in downturns (2008–09) suggests ZTS downside is limited, making limited‑risk long structures attractive. Watch unintended consequences: strong beats with weak guidance often lead to multiple compression — price in conservative guidance when sizing positions.

Key Decisions for Investors

• Establish a 2% long position in ZTS 1–2 days before Feb 12 earnings (or scale in to 2% by open), with a protective 8% stop and a 20% take‑profit target to capture expected beat-driven re-rating; convert to covered calls if up >15% within 30 days.
• Buy a defined‑risk call spread on PCRX sized 1–2% notional (6–8 week expiry spanning the earnings date): long ATM call, sell 10–15% OTM call to limit cost; target 30–40% upside on max spread value, cut at 12% mark‑to‑market loss.
• Allocate 1% notional to a Denali (DNLI) directional play using Apr/May 2026 call spreads ahead of the Apr 5 FDA decision (max loss = premium); if FDA approval occurs, trim to lock 40–60% gains within two weeks.
• Implement a pair trade: long ACAD (1.5% position) vs short SNY (1.5%) to capture superior product momentum vs FX exposure; rebalance after both companies report and exit if relative P/L moves against you by 10%.